A flexible PEG spacer was used to increase biocompatibility. Incorporation of the phosphodiester moiety in paclitaxel-containing nanoparticles enhanced the cancer-targeting capability. Dephosphorylation reactions in cancer cells liberated paclitaxel molecules from nanoparticles.